Cargando…
The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial
BACKGROUND: Calcification propensity is associated with the risk for cardiovascular events and death in end-stage renal disease patients. Here we investigated the effect of lowering serum phosphate with oral phosphate binder therapy on calcification propensity. METHODS: We performed an open-label, r...
Autores principales: | Thiem, Ursula, Soellradl, Ina, Robl, Bernhard, Watorek, Ewa, Blum, Sabine, Dumfarth, Alexandra, Marculescu, Rodrig, Pasch, Andreas, Haller, Maria C, Cejka, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886583/ https://www.ncbi.nlm.nih.gov/pubmed/33623689 http://dx.doi.org/10.1093/ckj/sfaa154 |
Ejemplares similares
-
Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells
por: Thiem, Ursula, et al.
Publicado: (2022) -
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2015) -
One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis
por: Kendrick, Jessica, et al.
Publicado: (2019) -
Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric
Oxyhydroxide
por: Cozzolino, Mario, et al.
Publicado: (2014) -
Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide
por: Gray, Kathryn, et al.
Publicado: (2019)